Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632672 | 0.80 | PDE4B (0.31) | — | |
| SCHEMBL5515534 | 0.80 | GAA (0.31) | — | |
| SCHEMBL765487 | 0.78 | — | — | |
| SCHEMBL209084 | 0.78 | — | — | |
| SCHEMBL1307795 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28644266 | 0.76 | GPR119 (0.30) | — | |
| SCHEMBL13818488 | 0.73 | — | — | |
| SCHEMBL11898330 | 0.73 | — | — | |
| SCHEMBL3818094 | 0.73 | — | — | |
| SCHEMBL87239 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | claimed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | claimed |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | CA1 4650/4885CA2 2534/4885CA4 4411/4885 |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA1 | CA1 4650/4885CA2 2534/4885CA4 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.